New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The phase 3b open-label, randomized controlled trial showed that patients treated with tirzepatide vs semaglutide lost an average of 20.2% vs 13.7% of their baseline weight over the 72 weeks.